ArticleClinica chimica acta; international journal of clinical chemistry2021
The impact of biosafety enhancement on stat laboratory quality metrics: Lessons from the COVID-19 pandemic.
Article in Clinica chimica acta; international journal of clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- When Brownian Motion Meets Clinical Laboratory Automation: A DLS-Inspired Autocorrelation Function for Characterizing Workflow Performance in Sample Processing.Diagnostics (Basel, Switzerland) · 2026Article
- The biosafety incident response competence scale for clinical nursing staff: a development and validation study.BMC nursing · 2024Article
- Agent-Based Simulation of Virus Testing in Certain-Exposure Time through Community Health Service Centers' Evaluation-A Case Study of Wuhan.Healthcare (Basel, Switzerland) · 2021Article
- The rise in preanalytical errors during COVID-19 pandemic.Biochemia medica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is unclear if implementation of biosafety action plans in response to the COVID-19 pandemic has affected laboratory quality metrics.
methodsThis retrospective study used quality data, including turnaround time (TAT) and number/type of unacceptable specimens from a stat laboratory supporting an outpatient medical clinic serving predominantly elderly cancer patients. Four months of data from the height of the COVID-19 pandemic (March-June 2020) were compared to the same months in 2019.
resultsMarch-May 2020 test volumes were decreased compared to 2019. June 2020 test volume was slightly increased compared to 2019. TATs in 2020 were similar/ slightly improved compared to the same months in 2019, due to shortened collect to receive and receive to verify TATs. The number and types of unacceptable specimens were similar in 2020 and 2019.
conclusionsDespite the challenges to the system caused by the pandemic, laboratory quality metrics were maintained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.